Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis
Assessment of Long Term, Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis
1 other identifier
observational
2,000
11 countries
84
Brief Summary
A prospective, observational post-market registry collecting outcomes through a 10-year post procedure follow-up for patients treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis (EXCC Device) or the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE Device) as a part of routine clinical practice.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2024
Longer than P75 for all trials
84 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 11, 2024
CompletedFirst Posted
Study publicly available on registry
January 23, 2024
CompletedStudy Start
First participant enrolled
May 7, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2042
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 30, 2042
February 5, 2026
February 1, 2026
18.4 years
January 11, 2024
February 2, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (11)
Deployment Technical Success
Successful access, delivery, and accurate deployment of the device to the intended location, and retrieval of the delivery system.
Time of Surgery
Lesion-related Mortality
Death related to the index endovascular procedure, secondary procedure associated with the index lesion or the registry device, or any death where the treated disease / index lesion or registry device caused or significantly contributed to the death
Day 30 through Year 10
Lesion Rupture
Rupture in the treated segment of the vessel (e.g., aorta or branch) verified with direct observation or Computed Tomographic Angiography (CTA) scan
Time of Surgery through Year 10
Lesion Enlargement
An increase in maximum vessel (e.g., aorta or treated branch) diameter of \> 5 mm in the region encompassed by the initial lesion as compared to baseline using orthogonal (i.e., perpendicular to the centerline) measurements on CTA scans
Time of Surgery through Year 10
Endoleaks
Perfusion of a treated lesion identified through imaging analysis
Time of Surgery through Year 10
Device Migration
Longitudinal movement of all or part of the device for a distance ≥ 10 mm, as confirmed by CTA scan, relative to anatomical landmarks and device positioning at the first post-operative CTA scan.
Time of Surgery through Year 10
Loss of aortic / branch patency
No flow or contrast detected through the implanted aortic and/or branch component (for branched devices) confirmed with imaging and/or direct observation.
Time of Surgery through Year 10
New onset renal failure
New onset sustained renal failure identified within 30 days of the index endovascular procedure, combined with requiring dialysis for \> 4 weeks
Time of Surgery through Day 30
Renal function deterioration
New onset of a decrease in eGFR \> 30% following treatment when compared to baseline eGFR.
Time of Surgery through Year 10
Device integrity events
wire fractures, stent kinking, disruption/tears in the graft component, or stent compression or invagination identified through imaging analysis
Time of Surgery through Year 10
Reintervention
Additional surgical or interventional procedure related to the treated disease / index lesion, the registry device, or to the treatment / procedure.
Time of Surgery through Year 10
Secondary Outcomes (2)
Characterization of remote data collection to supplement follow-up activities
Time of Surgery through Year 10
New onset buttock claudication / erectile dysfunction
Time of Surgery through Year 1
Study Arms (2)
GORE® EXCLUDER® Conformable AAA Endoprosthesis (EXCC Device)
Patients treated with the EXCC Device
GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE Device)
Patients treated with the IBE Device
Eligibility Criteria
Registry participants are derived from patients presenting with vascular disease that may benefit from the placement of an endovascular stent graft. The target registry population is patients who are treated with either EXCC or IBE Device at participating sites. This includes initial procedures and reinterventions (regardless of original intervention). Only patients who meet all the inclusion and none of the exclusion criteria will be included in the registry. The registry has been designed with broad eligibility criteria to optimize the visibility of overall registry device use. An integral requirement to the target subject population is that the decision to use a GORE® EXCLUDER® product has been made prior to considering the patient for possible registry participation.
You may qualify if:
- Patient or legally authorized representative (LAR) provides written authorization and/or consent per institution and geographical requirements
- Patient has been or is intended to be treated with an eligible registry device
- Patient is age ≥ 18 years at time of informed consent signature.
You may not qualify if:
- Patient who is, at the time of consent, unlikely to be available for standard of care (SOC) follow-up visits as defined by the site's guidelines and procedures.
- Patient is currently enrolled in or plans to enroll in any concurrent drug and/or device study within 12 months of Together Registry enrollment. Subjects cannot be enrolled in another Together Registry module protocol.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (90)
Central Arkansas Veteran's Healthcare System
Little Rock, Arkansas, 72205, United States
University of California - Irvine
Irvine, California, 92697, United States
University of Southern California
Los Angeles, California, 90033, United States
University of Southern California
Los Angeles, California, 90033, United States
Stanford University School of Medicine
Palo Alto, California, 94304, United States
Stanford University School of Medicine
Stanford, California, 94304, United States
Mount Sinai Vascular Institute
Miami Beach, Florida, 33140, United States
University of South Florida
Tampa, Florida, 33606, United States
University of South Florida
Tampa, Florida, 33606, United States
VA Medical Center- Atlanta
Atlanta, Georgia, 30033, United States
Emory Saint Joseph's Hospital
Atlanta, Georgia, 30322, United States
Augusta University Medical Center
Augusta, Georgia, 30912, United States
Atlanta VA Medical Center
Decatur, Georgia, 30033, United States
University of Chicago Hospital
Chicago, Illinois, 60637, United States
Endeavor Health
Evanston, Illinois, 60026, United States
St. Vincent Medical Group, Inc.
Indianapolis, Indiana, 46260, United States
University of Louisville
Louisville, Kentucky, 40202, United States
Our Lady of the Lake Regional Medical Center
Baton Rouge, Louisiana, 70808, United States
University of Maryland - Baltimore
Baltimore, Maryland, 21201, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
McLaren Heatlh Care Corporation
Bay City, Michigan, 48708, United States
Corewell Health Medical Group West
Grand Rapids, Michigan, 49546, United States
Minneapolis Heart Institute Foundation
Minneapolis, Minnesota, 55407, United States
Mayo Clinic
Rochester, Minnesota, 55905, United States
University of Missouri
Columbia, Missouri, 65212, United States
Cox Health
Springfield, Missouri, 65807, United States
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, 03766, United States
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, 03766, United States
University at Buffalo, Research Foundation
Buffalo, New York, 14203, United States
Mission Hospital
Asheville, North Carolina, 28801, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
Duke University Medical Center
Durham, North Carolina, 27710, United States
Duke Universtiy Medical Center
Durham, North Carolina, 27710, United States
Forsyth Medical Center
Winston-Salem, North Carolina, 27103, United States
Wake Forest Baptist
Winston-Salem, North Carolina, 27157, United States
Wake Forest Baptist
Winston-Salem, North Carolina, 27157, United States
University Hospitals - Cleveland Medical Center
Cleveland, Ohio, 44106, United States
Portland VA Health Care System
Portland, Oregon, 97239, United States
Portland VA Health Care System
Portland, Oregon, 97239, United States
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Prisma Health-Upstate
Greenville, South Carolina, 29615, United States
Prisma Health-Upstate
Greenville, South Carolina, 29615, United States
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
HCA Healthcare Research Institute/Columbia Medical Center of Plano
Plano, Texas, 75075, United States
Baylor Scott and White
Plano, Texas, 75093, United States
Intermountain Health
Murray, Utah, 84107, United States
Intermountain Health
Murray, Utah, 84107, United States
University of Utah
Salt Lake City, Utah, 84112, United States
University of Utah
Salt Lake City, Utah, 84112, United States
Inova Health Care Services
Falls Church, Virginia, 22042, United States
Sentara Heart Hospital
Norfolk, Virginia, 23507, United States
Sentara Heart Hospital
Norfolk, Virginia, 23507, United States
CAMC Health and Education and Research Institute, Inc
Charleston, West Virginia, 25304, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
John Hunter Hospital
New Lambton Heights, New South Wales, Australia
Gold Coast Hospital and Health Services
Southport, Queensland, Australia
Flinders Medical Centre (Vascular Unit)
Bedford Park, South Australia, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Royal Perth Hospital
Perth, Australia
Royal Prince Alfred Hospital
Sydney, Australia
Medizinische Universitat Wien
Vienna, Austria
Helsinki University Hospital (HYKS III)
Helsinki, Finland
Helsinki University Hospital (HYKS III)
Helsinki, Finland
Wellbeing Services County of Pirkanmaa Tampere University Hospital
Tampere, Finland
Wellbeing Services County of Pirkanmaa
Tampere, Finland
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
Azienda Ospedaliero Universitaria delle Marche Ospedali Riuniti di Ancona
Ancona, Italy
Azienda Ospedaliero Universitaria Policlinico di Bari
Bari, Italy
Azienda Ospedaliero Universitaria Policlinico di Bari
Bari, Italy
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy
AOU Città della Salute e della Scienza di Torino Ospedale S.Giovanni Battista- Molinette
Torino, Italy
Azienda Ospedaliera Universitaria Integrata Verona
Verona, Italy
Amsterdam UMC Research BV
Amsterdam, Netherlands
Stichting Elisabeth-Tweesteden Ziekenhuis
Tilburg, Netherlands
VieCuri Medical Center
Venlo, Netherlands
Clinical Trials New Zealand Limited - Waikato Hospital
Hamilton, Waikato Region, New Zealand
Auckland District Health Board Charitable Trust
Auckland, New Zealand
Uniwersytecki Szpital Kliniczny NR 1 W Lublinie
Lublin, Poland
Hospital De La Santa Creu i Sant Pau
Barcelona, Spain
Hospital Universitario Virgen del Rocío
Seville, Spain
Karolinska University Hospital
Stockholm, Sweden
Karolinska University Hospital
Stockholm, Sweden
University Hospitals of Leicester NHS Trust
Leicester, United Kingdom
Countess of Chester Hospital NHS Foundation Trust
Liverpool, United Kingdom
Countess of Chester Hospital NHS Foundation Trust
Liverpool, United Kingdom
Imperial College Healthcare NHS Trust, St. Mary's Hospital
London, United Kingdom
St Thomas Hospital - Guys and St. Thomas' NHS
London, United Kingdom
St Thomas Hospital - Guys and St. Thomas' NHS
London, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
S. Han
University of Southern California
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 10 Years
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 11, 2024
First Posted
January 23, 2024
Study Start
May 7, 2024
Primary Completion (Estimated)
September 30, 2042
Study Completion (Estimated)
September 30, 2042
Last Updated
February 5, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will share
- Time Frame
- Sharing of IPD will not routinely be performed and is contingent on an assessment of the researcher's proposal for novelty or value in advancing educational, quality or medical practice objectives in use of this data.
- Access Criteria
- See above
Data to be shared will be pseudo-anonymized with subject names and birthdates removed, but information such as procedure date will not.